Elicio Therapeutics (ELTX) Payables (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Payables for 7 consecutive years, with $839000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 78.29% year-over-year to $839000.0; the trailing twelve-month figure through Jun 2026 stood at $839000.0 (down 78.29% YoY), and the FY2025 full-year result was $672000.0, down 35.26% from the prior year.
• Payables grew to $839000.0 in Q2 2026 per ELTX's latest filing, from $272000.0 in the prior quarter.
• Across five years, Payables topped out at $4.4 million in Q3 2023 and bottomed at $272000.0 in Q1 2026.
• Historically, Payables has averaged $2.2 million across 5 years, with a median of $2.1 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Payables surged 266.35% in 2025, then tumbled 93.26% in 2026.
• Over 5 years, Payables stood at $2.8 million in 2022, then soared by 55.76% to $4.4 million in 2023, then slumped by 76.24% to $1.0 million in 2024, then sank by 35.26% to $672000.0 in 2025, then increased by 24.85% to $839000.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $839000.0, $272000.0, and $672000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.